Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences to Present at Two Upcoming Investor Conferences

Business Wire September 6, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on GILD, ITMN, MDVN and PBYI

ACCESS Newswire September 6, 2013

AAPL, INTC, HIMX and GILD added to NASDAQ Active Stock Watch List at EPR

ACCESS Newswire August 19, 2013

The Straight Truth, Investing in EL, BA, CVX and GILD

Marketwired August 16, 2013

Secrets to Making Money in GILD, NEM, MOS and DOW

Marketwired August 13, 2013

In the Know, Smart Investing in PG, GILD, ESRX and EMC

Marketwired August 9, 2013

Strategy Behind Our Success, We Get in Early: LNKD, DVN, GILD and GMCR

Marketwired August 8, 2013

GMCR, LINE, AAPL and GILD added to NASDAQ Active Stock Watch List at EPR

ACCESS Newswire August 8, 2013

Galectin Therapeutics Lab Studies Shows Robust Results in Treating Lung Fibrosis

ACCESS Newswire August 6, 2013

Key to Success, How to Profit: PG, MA, TSN and GILD

Marketwired August 6, 2013

Before the Crowd, How We Found MRK, GILD, KO and JPM

Marketwired July 30, 2013

Five Star Equities Issues New Research Reports on GILD, HAL, QLIK and VRTX

ACCESS Newswire July 29, 2013

The Reason It Trades, What's Moving TQNT, SE, GILD and TER

Marketwired July 26, 2013

Gilead Sciences Announces Second Quarter 2013 Financial Results

Business Wire July 25, 2013

The Real Story Behind PM, MU, GILD and AMT

Marketwired July 25, 2013

Perfect Trade Setups, How to Play AMD, GILD and QCOM

Marketwired July 25, 2013

Gilead Sciences to Release Second Quarter 2013 Financial Results on Thursday, July 25, 2013

Business Wire July 18, 2013

Hepatitis C Important, But Investors Should be Focusing on Fatty Liver Disease and Galectin

ACCESS Newswire July 17, 2013

Gilead Sciences, Halozyme Therapeutics, Santarus, NPS Pharma, and InterMune Under AAAResearchReports.com Microscope

PR Newswire July 2, 2013

Positive Interim R&D Results, Opening of New Laboratories, and Prestigious Awards Underline Growth Potential in Biotech Companies - Research Report on Gilead, Biogen Idec, Ariad, Incyte, and Sequenom

PR Newswire July 1, 2013